Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Greg MoeckLeanne B GasinkRodrigo Elisandro MendesLeah N WoosleyMaryBeth DorrHongzi ChenFlorian M E WagenlehnerTim HenkelPaul C McGovernPublished in: Antimicrobial agents and chemotherapy (2024)
This study is registered with ClinicalTrials.gov as NCT03840148.